Literature DB >> 23793199

Translation into Brazilian Portuguese and validation of the psoriasis family index.

Juliana Catucci Boza1, Mohammad K A Basra, Rafaela Caminha Vanin, Renata Rosa Carvalho, Magda Blessmann Weber, Tania Ferreira Cestari.   

Abstract

Psoriasis Family Index is a quality of life instrument for family members of patients with psoriasis developed in English. The aims of this study were to translate the Psoriasis Family Index into Brazilian Portuguese, culturally adapt it and verify its reliability and validity. The study followed these two steps: 1) Translation, linguistic and cultural adaptation, 2) Validation. The translated Psoriasis Family Index showed high internal consistency and high test-retest reliability, confirming its reproducibility. The Portuguese version of the Psoriasis Family Index was validated for our population and can be recommended as a reliable instrument to assess the QoL of family members and partners of patients with psoriasis.

Entities:  

Mesh:

Year:  2013        PMID: 23793199      PMCID: PMC3754393          DOI: 10.1590/abd1806-4841.20131911

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


Psoriasis is a chronic inflammatory disease affecting skin, scalp, nails and occasionally joints. Similarly to other chronic skin diseases, the impact of psoriasis extends beyond the patients' quality of life (QoL), affecting their family and partners.[1,2] Measuring the secondary impact of psoriasis on the health-related quality of life (HRQoL) of family members of psoriasis patients is a fundamental aspect of the treatment of the disease. Moreover, it is helpful as an additional instrument to evaluate endpoints in clinical practice and studies.[3,4] The Psoriasis Family Index (PFI) is a 15-item questionnaire that was developed and validated in the Department of Dermatology of the Cardiff University School of Medicine by Finlay et al.[4] The authors published the preliminary results and concluded that PFI was easy to understand, administer and answer, in addition to being effective in evaluating the impact of psoriasis on family members/relatives of patients with the disease. The validated questionnaires for the measurement of QoL are mostly developed for English speaking populations. Therefore, it is usually necessary to adapt these questionnaires in terms of language and culture. With this in mind, the aim of this study was to translate the PFI from English into Brazilian Portuguese, culturally adapt it to our population, and verify its reliability and validity. The study followed the steps proposed by the World Health Organization for QoL questionnaires and was developed in agreement with the original authors in 2 steps: 1. Translation and linguistic and cultural adaptation: This part of the study was conducted by the joint work of 10 pairs of patient/relatives, 3 translators, a psychiatrist, a nurse and the English and Portuguese authors; 2. Validation: The study population comprised a convenience sample of psoriasis patients and family members or partners accompanying patients to their routine outpatient appointments at the Dermatology Outpatient Clinic of the Clinics Hospital of Porto Alegre. For the family members/partners to be included in the study, the patient had to have psoriasis diagnosed more than 1 year before recruitment. The family members/partners were excluded if they suffered from any skin disease, including psoriasis or any chronic nona-dermatological condition. Disease severity was measured by the Psoriasis Area and Severity Index (PASI)6 and Patient Quality of Life (QoL) was assessed by the Dermatology Life Quality Index (DLQI)7 and Psoriasis Disability Index (PDI).[5-8] The partners or family members recorded how they perceived the severity of the patients' psoriasis on a 0-10 visual analogue scale (Family Global Assessment, FGA), with 0 indicating cleared psoriasis and 10 indicating very severe psoriasis. Family members' QoL was assessed by the Brazilian version of PFI. A total of 68 pairs of a psoriasis patient and a close relative/partner formed the baseline validation population. The BP-PFI (Brazilian Portuguese Psoriasis Family Index) showed high internal consistency (Cronbach's alpha = 0.91) and high test-retest reliability (intraclass correlation coefficient = 0.70). The mean score of the population for PFI-15 BP was 11 (range = 0-34), PASI was 7.39 (range = 0.3-69.6), DLQI was 8 (range: 0-28), PDI was 12 (range: 0-41), and FGA was 6.09 (range: 2-10). Besides that, there was a significant correlation between families' PFI scores and DLQI scores (r = 0.5, p<0.001), PDI scores (r = 0.61, p<0.001), PASI scores (r = 0.38, p<0.001) and FGA (r = 0.49, p<0.01), as shown in graph 1.
GRAPH 1

Scores of PASI, PDI, DLQI, FGA and PFI

Scores of PASI, PDI, DLQI, FGA and PFI Table 1 demonstrates the results of the BP-PFI in comparison with the original version.
Table 1

Results of the original PFI in comparison with the Brazilian version of PFI

Original PFITranslated PFI
Cronbach's alpha0.860.91
CCI*0.930.70
PFI X DLQIr= 0.54r=0.50
PFI X PDIr= 0.59r=0.61
PFI X PASIr=0.43r=0.38
PASI X FGAr=0.49r=0.54
Results of the original PFI in comparison with the Brazilian version of PFI Psoriasis has a clear impact on the patient's QoL and on their family. The secondary impact of psoriasis on family members and its implications for the patient's QoL and severity of the disease have been evaluated in recent studies.[2-4] The use of PFI could be a complementary tool in measuring the impact of psoriasis and showing different aspects of a patient's life. PFI allows us to capture specific issues related to psoriasis, including some extra housework such as laundry and cleaning due to messy, greasy scales treatment and vacuuming of skin flakes. The Brazilian Portuguese version of PFI was validated for our population and it could be recommended as a reliable measure to assess the QoL of family members and partners of Brazilian patients with psoriasis.
  7 in total

1.  Psoriasis--an index of disability.

Authors:  A Y Finlay; S E Kelly
Journal:  Clin Exp Dermatol       Date:  1987-01       Impact factor: 3.470

2.  Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

Authors:  A Y Finlay; G K Khan
Journal:  Clin Exp Dermatol       Date:  1994-05       Impact factor: 3.470

Review 3.  Two decades experience of the Psoriasis Disability Index.

Authors:  Victoria J Lewis; Andrew Y Finlay
Journal:  Dermatology       Date:  2005       Impact factor: 5.366

4.  The psoriasis family index: preliminary results of validation of a quality of life instrument for family members of patients with psoriasis.

Authors:  A M Eghlileb; M K A Basra; A Y Finlay
Journal:  Dermatology       Date:  2009-03-13       Impact factor: 5.366

5.  Severe psoriasis--oral therapy with a new retinoid.

Authors:  T Fredriksson; U Pettersson
Journal:  Dermatologica       Date:  1978

6.  Psoriasis has a major secondary impact on the lives of family members and partners.

Authors:  A M Eghlileb; E E G Davies; A Y Finlay
Journal:  Br J Dermatol       Date:  2007-04-25       Impact factor: 9.302

7.  Measurement of family impact of skin disease: further validation of the Family Dermatology Life Quality Index (FDLQI).

Authors:  M K A Basra; O Edmunds; M S Salek; A Y Finlay
Journal:  J Eur Acad Dermatol Venereol       Date:  2008-02-27       Impact factor: 6.166

  7 in total
  1 in total

1.  Translation, cross-cultural adaptation and validation of the vitiligo-specific health-related quality of life instrument (VitiQoL) into Brazilian Portuguese.

Authors:  Juliana Catucci Boza; Roopal V Kundu; Amanda Fabbrin; Roberta Horn; Natalia Giongo; Tania Ferreira Cestari
Journal:  An Bras Dermatol       Date:  2015-06-01       Impact factor: 1.896

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.